The u.s. biotechnology company Novavax, which has received$ 1.6 billion from Washington to develop a vaccine against the coronavirus, has announced on Tuesday that its experimental vaccine had produced high levels of antibodies in a few dozens of volunteers.
Novavax is one of the six companies in which the government of Donald Trump has invested heavily since march.
The two projects western the most advanced in terms of clinical trials are those of the british university of Oxford, together with the laboratory, AstraZeneca, and the u.s. biotechnology company Moderna, associated with Institutes american health, both of which have initiated their phase 3 trials on thousands and ultimately tens of thousands of participants.
But the first phase of clinical trials of vaccines is always wearing on a few dozen healthy participants, in order to verify that the vaccine is not toxic, and see if it triggers an initial immune response.
The participants of this phase 1 trial of Novavax, which included 131 people in Australia, of which 50, with placebos, have developed antibodies after the first dose of the vaccine, including neutralizing antibodies to “number of them”, said the company in a press release.
After the second dose, all participants vaccinees developed neutralizing antibodies.
The experimental vaccine also triggered a T cell response, the other component of the immune response against a virus.
The injections have caused adverse health effects, including pain at the injection site, headache, fatigue, and muscle aches. After the second dose, the effects were more severe, but none of them has reached serious level, according to Novavax.
These results have been submitted for publication by a scientific journal. For the moment, they have not been assessed independently.
If this vaccine was proven at the end of trials of greater magnitude, this would be the first to be authorized from the company. Donald Trump paid a visit last week to the site of production of the experimental doses.